Bender Robert & Associates Clovis Oncology, Inc. Transaction History

Bender Robert & Associates

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 19, 2022	BUY	$0.63 - $2.96 $31,500 - $148,000	50,000 New	50,000 $90,000
Q2 2021 Jul 16, 2021	SELL	$5.02 - $7.05 $250,999 - $352,500	-50,000 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$4.81 - $10.34 $240,499 - $517,000	50,000 New	50,000 $351,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Bender Robert & Associates, based on Form 13F filings with the SEC.

Stay updated on Bender Robert & Associates with notifications on news.